Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Amagma was founded in 2019 by serial entrepreneurs Tillman Gerngross, Ph.D. and Leonard Zon, M.D., to develop novel antibody therapies targeting diseases resulting from the dysfunction of essential proteases and other enzymes. These targets have long been of interest to the biopharmaceutical industry, but, despite this, there remain significant unmet medical needs across the many inflammatory conditions caused by protease dysf...
Amagma was founded in 2019 by serial entrepreneurs Tillman Gerngross, Ph.D. and Leonard Zon, M.D., to develop novel antibody therapies targeting diseases resulting from the dysfunction of essential proteases and other enzymes. These targets have long been of interest to the biopharmaceutical industry, but, despite this, there remain significant unmet medical needs across the many inflammatory conditions caused by protease dysfunction. We believe that antibodies hold the greatest potential to successfully address these needs and have built a proprietary platform.

List your booth number for exhibitions, ask us